Home
About
Warning Letter Wednesday
Work With Me
Testimonials
Appearances
Press
Regulatory Blog
Resources
More
Asa Waldstein
Community, Compliance, Natural Health
Marketing Strategy Compliance √
Remove testimonials with claims
3/15/23
Old social posts are âactiveâ marketing
2/22/23
Learning from otherâs mistakes is a good strategy
2/1/23
Remove COVID claims including on YouTube
1/11/23
Discussing ingredient benefits is marketing
12/21/22
11/30/22
Common labeling errors can be avoided
11/9/22
Opioid support claims are high risk
10/19/22
Webinars are âfair gameâ for enforcement
3/8/23
Hire experts to help with 483 responses
2/15/23
Nutrient content claims must be compliant
1/25/23
Expect arterial health claims to be cited in the future
1/4/23
Do not engage with customer âdiseaseâ testimonials
12/14/22
CBD enforcement is top of mind for FDA
11/23/22
Distributors are responsible for the products they sell
11/2/22
Following label format is important
10/12/22
Scan marketing for âmid-riskâ heart health claims
3/1/23
Key GMP learning opportunities explored
2/8/23
FDA will test suspicious products for drugs
1/18/23
Study citations are marketing
12/28/22
Product claims must be compliant
12/7/22
Ingredient research can be considered a marketing claim
11/16/22
Discussing ingredient benefits is a marketing claim
10/26/22
âBrain Fogâ claims related to Covid will attract scrutiny
10/5/22